for the Thyroid Studies Collaboration IMPORTANCE Some experts suggest that serum thyrotropin levels in the upper part of the current reference range should be considered abnormal, an approach that would reclassify many individuals as having mild hypothyroidism. Health hazards associated with such thyrotropin levels are poorly documented, but conflicting evidence suggests that thyrotropin levels in the upper part of the reference range may be associated with an increased risk of coronary heart disease (CHD).
studies suggests that individuals with hypothyroidism may be at increased risk of coronary heart disease (CHD) events and CHD mortality. 2 Among people with apparently normal thyroid function, thyrotropin levels in the upper part of the reference range may indicate an early stage of hypothyroidism. [3] [4] [5] [6] In addition, such thyrotropin levels have been associated with an adverse cardiovascular risk profile that includes high levels of non-high-density lipoprotein cholesterol, triglycerides, blood pressure, and body mass index, as well as low levels of high-density lipoprotein cholesterol. 7-11 Therefore, it seems plausible that differences in thyroid function within the population reference range may be differentially associated with CHD risk. In support of this hypothesis, the results of one cohort study suggested that thyrotropin levels within the reference range may be positively associated with CHD mortality in women, but not in men. 12, 13 In contrast, the results of other studies do not suggest any association between thyrotropin levels within the reference range and the risk of CHD events, 14 vascular mortality, 15 or need for coronary revascularization. 16 The definition of the clinically normal range for thyroid function is controversial. Some experts have suggested that the upper thyrotropin reference limit should be lowered from approximately 4.5 to 2.5 or 3.0 mIU/L since higher thyrotropin levels may indicate early-stage hypothyroidism. 17 Others disagree, 18-21 because many people with a healthy thyroid gland would thereby be classified with abnormal thyroid function, and there is no firm evidence that thyrotropin levels in the upper part of the reference range are associated with health consequences that would benefit from early recognition and treatment of hypothyroidism. Most research on such potential consequences has focused on CHD and its risk factors, 11 and a recent review concluded that there was good evidence for associations between higher thyrotropin levels within the reference range and cardiovascular risk factors and events. 11 However, most of this evidence comes from cross-sectional studies, which are inferior to prospective studies for causal inference.
To clarify whether people with thyrotropin levels in the upper part of the reference range may be at increased risk of CHD, we performed a meta-analysis of individual participant data in 14 cohort studies included in the Thyroid Studies Collaboration consortium.
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Methods
Cohorts
The Thyroid Studies Collaboration consists of cohorts with thyroid function measurements at baseline and prospective follow-up of CHD outcomes. Its original purpose was to examine CHD risk among people with subclinical thyroid dysfunction, and suitable cohorts for that purpose were identified through systematic literature searches of the MEDLINE and EMBASE databases from January 1, 1950, to June 30, 2011, as previously described. we used a reference range of 0.5 to 5.9 mIU/L because the firstgeneration thyrotropin assay used in that study yields consistently higher levels than measurements of current assays. 2 Among 55 935 individuals who fulfilled the criteria for inclusion, we excluded 523 people (0.9%) without information on smoking habits or follow-up information, leaving a total of 55 412 participants for analysis. We examined the risk of CHD mortality in all cohorts. In cohorts with information on both nonfatal and fatal CHD events, we also examined risks of a first-time CHD event (combined end point of CHD mortality, myocardial infarction, coronary artery revascularization, incident angina pectoris, or hospital diagnosis of CHD) and a first-time hard CHD event (combined end point of CHD mortality or myocardial infarction). Types of CHD event data available in each cohort are described in eTable 1 in the Supplement.
Statistical Analysis
For each cohort, we used separate Cox proportional hazard models to estimate the associations of thyrotropin levels with each CHD outcome. We then calculated pooled estimates across cohorts using random-effects models based on the variance model described by DerSimonian and Laird.
39,40 Heterogeneity across cohorts was assessed by the I 2 statistic, which describes the proportion of the total variation across studies attributable to heterogeneity rather than to chance. We adjusted for age (by using attained age as the time scale), sex, and smoking status 41 High thyrotropin levels may be more likely to indicate low thyroid function in people with TPO antibodies in serum. 5, 6 Among cohorts with TPO antibody measurements at baseline, we therefore estimated the risk of CHD by combinations of thyrotropin level (0.45-2.49 or 2.50-4.49 mIU/L) and TPO antibody status (positive or negative using study-specific cutoff points as reported in eTable 1 in the Supplement).
In addition, we examined risks of CHD outcomes by free thyroxine (FT 4 ) levels at baseline, analyzing FT 4 both as a continuous variable and by categories. Because the different FT 4 assays are not standardized and yield different reference limits, 42 we used quartile categories based on the quartile distributions within each cohort. As reference, we used the highest quartile, which suggests relatively high thyroid function. After observing an association between FT 4 categories and CHD risk, we examined whether there was statistical evidence for a U-shaped association between FT 4 and CHD risk as expressed by the P value for the squared value of FT 4 levels. We performed a set of sensitivity analyses to evaluate the robustness of the findings. First, because nonthyroidal illness may influence thyroid function test results, 43 we repeated the analyses after excluding the first 2 years of follow-up to reduce the influence that preclinical CHD at baseline could have on the results. Second, we repeated the analyses with statistical adjustment for body mass index at baseline (expressed by restricted cubic spline) because adiposity, in addition to being a possible mediator between thyroid function and CHD, 10 may be a common cause of high thyrotropin levels and CHD. 44 Third, we excluded participants with diabetes mellitus at baseline since diabetes may be associated with thyroid dysfunction 45,46 and silent CHD. 47 Fourth, we restricted the analyses to never-smokers to avoid residual confounding from smoking. 41 Fifth, in cohorts with information on use of thyroid medication during follow-up, we examined whether hazard ratios (HRs) for CHD outcomes changed after exclusion of participants who began therapy with thyroid medication during follow-up. Sixth, we restricted the analyses to the 11 cohorts that were identified through the systematic literature searches. Seventh, we repeated the analyses after excluding the Study of Health in Pomerania cohort, which was formerly iodine deficient and had a substantially different studyspecific reference range for thyrotropin (0.25-2.12 mIU/L).
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Eighth, we repeated the analyses after excluding the Whickham Survey 31,34 (which started follow-up in the 1970s) and the Leiden 85-Plus Study 27 (which only included participants aged 85 years). Ninth, we repeated the analysis of FT 4 and CHD risk after excluding participants with FT 4 levels outside the study-specific reference ranges reported in eTable 1 in the Supplement. Because thyroid function could influence the risk of CHD through thyroid hormone effects on blood pressure and cholesterol levels, 1 whenever associations with CHD outcomes were observed, we examined whether the HRs were altered by statistical adjustment for systolic blood pressure and total serum cholesterol levels at baseline. All analyses were performed using Stata, version 13.1 for Windows (StataCorp LP).
Results
Characteristics of the 14 cohorts are given in Table 1 (Figure) . The association did not differ by sex or age ( Table 2) .
Ten cohorts had information on both fatal and nonfatal CHD events. Among 48 875 individuals in these cohorts, 4666 people (9.5%) experienced a first-time CHD event during 533 408 person-years of follow-up. For each 1-mIU/L higher thyrotropin level at baseline, the HR for a first-time CHD event was 1.00 (95% CI, 0.97-1.03). The association was homogeneous across studies (I 2 , 0%) ( Figure) and did not differ by sex or age (Table 2) . In 7 cohorts, the risk of hard CHD events (CHD mortality or myocardial infarction) could be examined, and 2488 (7.3%) of 34 256 individuals in these cohorts experienced a firsttime hard CHD event during 356 400 person-years of followup. There was no association between thyrotropin levels and the risk of a first-time hard CHD event, and the HRs did not substantially differ from those of any CHD event (Table 2 and Figure) .
The sensitivity analyses of thyrotropin levels and CHD risk yielded results similar to the main analysis (eTable 3 in the Supplement). We also examined CHD risk by categories of thyrotropin at baseline but found no associations with risk of CHD mortality or CHD events (Table 3) .
Among cohorts with TPO antibody measurement at baseline, we examined the combined association of thyrotropin level and TPO antibody status with the risk of CHD mortality (4 cohorts), a first-time CHD event (3 cohorts), and a first-time hard CHD event (2 cohorts). There was no evidence that high (2.50-4.49 mIU/L) thyrotropin levels combined with TPO antibodies were associated with increased CHD risk compared with low (0.45-2.49 mIU/L) thyrotropin levels and no TPO antibodies (eTable 4 in the Supplement).
In addition, we examined associations of FT 4 levels at baseline with risk of CHD. We observed no linear associations of FT 4 levels with risk of CHD mortality (9 cohorts) or a first-time CHD event (6 cohorts) (eFigure in the Supplement), and the associations did not convincingly differ by sex or age (eTable 5 in the Supplement). In analyses by FT 4 categories, the risk of CHD mortality and CHD events did not substantially differ between participants with low (lowest quartile) and high (highest quartile) FT 4 levels (eTable 6 in the Supplement). However, the results suggested a U-shaped association between FT 4 level and CHD risk since participants with FT 4 levels in the second quartile had lower risks of CHD mortality (HR, 0.76 [95% CI, 0.57-0.99]) and CHD events (HR, 0.73 [95% CI, 0.58-0.94]) compared with participants with high (highest quartile) FT 4 levels. Nonetheless, the P value for squared FT 4 levels did not show statistically significant evidence of a U-shaped association of FT 4 level with CHD risk (P = .48 for CHD mortality and P = .22 for CHD events). Associations between FT 4 level and risk of hard CHD events could be examined only in 4 cohorts of elderly participants, but estimates were similar to those of any CHD event (eTable 5, eTable 6, and eFigure in the Supplement).
Sensitivity analyses of FT 4 levels and CHD risk yielded results similar to the main analysis (eTable 7 and eTable 8 in the Supplement), except that when the analysis was restricted to participants with FT 4 levels within the reference range, there was statistically significant evidence to suggest a Copyright 2015 American Medical Association. All rights reserved.
U-shaped association between FT 4 and risk of CHD events (squared value of FT 4 levels, P = .02). The association of FT 4 categories with CHD risk remained essentially unchanged after adjustment for baseline levels of systolic blood pressure and total serum cholesterol levels (eTable 8 in the Supplement). 
Discussion
In this individual participant data analysis of 55 412 people from 14 cohorts, differences in thyrotropin levels within the reference range were not associated with risk of CHD mortality or CHD events. Associations between thyrotropin levels within the reference range and risk of CHD have been examined in a few cohort studies, 12-16 2 of which are included in the present individual participant data analysis. [12] [13] [14] In one of these cohorts, each 1-mIU/L higher thyrotropin level at baseline was associated with a 37% higher risk of CHD mortality in women, 12 but there was no corresponding association in men and no association of thyrotropin with risk of hospitalization for myocardial infarction. 12, 13 In other cohorts, there were no associations of thyrotropin levels with risk of CHD events, 14 vascular mortality, 15 or coronary revascularizations. 16 Compared with the previous cohort studies, a major strength of this individual participant data analysis is the large sample size, which enabled more precise risk estimates for both fatal and total CHD events. The use of individuallevel data enabled similar classification of exposures and covariates across cohorts. In cohorts in which medication was recorded during follow-up, few participants initiated therapy with thyroid medication, and risk estimates for CHD were similar after exclusion of these individuals. Therefore, use of thyroid medication is not likely to have substantially influenced our results. The results of this meta-analysis strongly suggest that differences in thyrotropin levels within the population reference range are not associated with the risk of CHD and that the previously reported association between thyrotropin levels within the reference range and CHD mortality 12, 13 is likely to be a chance finding. A limitation of the present study is that only one measurement of thyroid function at baseline was available, and we could not specifically examine the risk of CHD among people whose thyrotropin level remained in the upper part of the reference range over time. Also, few cohorts included measurement of TPO antibodies, so the risk of CHD among people with thyrotropin levels in the upper part of the reference range combined with the presence of TPO antibodies could not be estimated with high precision.
Of the different measures of thyroid function, we emphasized serum thyrotropin levels in this study for 2 reasons. First, thyrotropin levels in the upper part of the reference range are sometimes a marker of early-stage hypothyroidism, as indicated by an increased prevalence of autoimmune thyroid disease and risk of future hypothyroidism.
3-6 Second, serum thyrotropin is considered to be the most sensitive marker for change in thyroid function since pituitary thyrotropin secretion responds to even slight changes in circulating thyroid hormone levels. 49 The discrepancy in our data between thyrotropin showing no association but FT 4 showing a possible U-shaped association with CHD risk was therefore unexpected. It has been suggested that serum thyrotropin, although a reflection of thyroid-pituitary feedback, may not reflect thyroid status in every organ. excluding those receiving levothyroxine in association with hyperthyroidism, pituitary disease, thyroid surgery, pregnancy, or use of thyroid-altering medication, reported an increase in the use of levothyroxine for borderline elevated thyrotropin levels, and approximately 6% had a thyrotropin level of less than 4.0 mIU/L at the initiation of levothyroxine therapy. This finding suggests that levothyroxine is being prescribed to many individuals in whom its clinical benefit is uncertain. Knowledge about health hazards associated with thyrotropin in the upper part of the reference range is important to inform a lowering of the upper thyrotropin reference limit. Cardiovascular hazards have been suggested by cross-sectional studies 7-11 that found positive associations of thyrotropin with adverse lipid levels and higher blood pressure and body mass index. However, recent longitudinal evidence suggests that associations are very weak, if any, between thyrotropin levels within the reference range and future levels of serum lipids, blood pressure, and body mass index. 58, 59 In line with those findings, the present study provides prospective evidence indicating that individuals with thyrotropin levels in the upper part of the reference range are not at increased risk of CHD. The tween people with mildly elevated serum thyrotropin levels (4.5-6.9 mIU/L) and people with thyrotropin within the reference range.
In this study, we examined associations between thyrotropin levels and future CHD among people without previously known cardiovascular disease. Our results do not inform whether thyrotropin levels measured after the clinical onset of cardiovascular disease may have prognostic value, as suggested by some evidence. 60 In addition, we did not examine whether levels of thyroid function tests within the reference ranges may be differentially associated with all-cause mortality 16, 61, 62 or the risk of non-CHD outcomes, such as atrial fibrillation, 62, 63 heart failure, 62 fractures, 64 dementia, 62, 65 chronic kidney disease 66 or cancer mortality, 61 as suggested in some prospective studies. However, except for a modestly increased risk of chronic kidney disease, 66 these studies did not show increased disease risk among people with thyrotropin levels in the upper part of the reference range and thus do not provide evidence in support of lowering the upper thyrotropin reference limit.
Conclusions
In this individual participant data analysis of 55 412 individuals from 14 cohorts, thyrotropin levels in the upper part of the reference range were not associated with an increased risk of CHD events or CHD mortality. This finding suggests that differences in thyroid function within the population reference range do not influence the risk of CHD. Increased risk of CHD does not appear to be a reason for lowering the upper thyrotropin reference limit.
